INVESTOR PRESENTATION 2019 Better Data, Better Health WHO ARE WE? - - PowerPoint PPT Presentation

▶

Dec 06, 2023 417 likes •574 views

TSX-V: AVCR OTCQB: AVCRF INVESTOR PRESENTATION 2019 Better Data, Better Health WHO ARE WE? Avricore is a total health innovator capitalizing on technological advancements and consumer health trends, offering consumers, health providers

SLIDE 1

INVESTOR PRESENTATION 2019

Better Data, Better Health

TSX-V: AVCR  OTCQB: AVCRF

SLIDE 2

WHO ARE WE?

Avricore is a total health innovator capitalizing on technological advancements and consumer health trends, offering consumers, health providers and life- science companies the ability to take control of both spending and health outcomes. We intend on become the world’s largest health data company and are utilizing point-of-care technologies within community pharmacy to achieve this. www.avricorehealth.com

SLIDE 3

QUICK OVERVIEW

➤ Converted from VANC Pharmaceuticals, a generic drug maker

with 91 generic offerings in 2018 to become Avricore Health Inc.

➤ We maintain the ownership of these dormant licences. ➤ Avricore is currently selling Hema-fer, an OTC iron supplement, to

pharmacies across Canada.

➤ In the transition, Avricore purchased two technologies, the

Avricore Platform (formerly Corozon Platform) and HealthTab.

➤ The Company’s primary focus today is on developing a network

f point-of-care analyzers that utilizes its HealthTab software in

community pharmacy.

SLIDE 4

W E L C O M E T O H E A LT H TA B A N D T H E R A S T R M O D E L

Patient consent Personalized Reports De-identified Realtime Data

The patient driven rapid access, safety test reporting system (RASTR)

SLIDE 5

2 panels, 21 results Turnkey System

In-store kiosk Lab-accurate analyzer Secure online results

SLIDE 6

Proven point-of-care screening system,

designed to support pharmacists evolving role.

Empowers patients to be proactive about

their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease.

Simple, fast, lab-accurate, and requires

just a few drops of blood from a finger stick.

Results can be printed in-store or

accessed securely online.

Watch short video here and visit our

HealthTab website.

SLIDE 7

A network of HealthTab systems utilizing the Piccolo

Analyzer in community pharmacies.

Running panels on consumers utilizing finger stick

sample, monitoring up to 21 key bio-markers, and/or customizable tests.

Allows for API integration for better data flow and

customization.

Provides harmonized, real-time data on consumer

health.

R A S T R M O D E L

1. The client purchases the drug or other health product.
2. The pharmacy leases the analyzers at a reasonable cost to become a part of the

network.

3. The drug maker pays to access the network and sponsors test fees for consumer.

SLIDE 8

BOARD DIRECTORS

Bob Rai - CEO & director David Hall - Chairman & Director Alan Arnstein - Director

  BOARD ADVISORS

Ray Chepsiuk – Board Advisor Sherif Guorgui - Board Advisor David Huston- Board Advisor

OUR TEAM

Kevin Strong - CFO Rodger Seccombe - Head of HealthTab Division

MANAGEMENT

Dr. Robert Sindelar - Director

David Farnfield – Director Mark Zhou – Board Advisor Philippe Ungat – Board Advisor Deena Siblock - Corporate Secretary Hector Bremner – EVP , Strategic Communications/Public Affairs For more information on our team, please visit our website

SLIDE 9

PROJECTIONS

2,000

4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 2019 2020 2021 2022 2023 2024 2025

Annual Sales

('000 CAD)

(2,000)

2,000

4,000 6,000 8,000 10,000 12,000 2019 2020 2021 2022 2023 2024 2025

Annual Cash-Flow

('000 CAD)

SLIDE 10

PROJECTIONS

Equity Investment 3,900 CFs (before-tax) (3,900)

1,117

7,453 9,539 9,791 10,509 10,688 10,688 10,688 10,688 CFs (after-tax) (3,900)

1,096

5,933 7,432 7,404 7,992 8,120 8,096 8,086 8,081 Before tax IRR 78% NPV 29,902 After tax IRR 68% NPV 22,211

Our business model presents an exciting opportunity for investment. Cash flows and revenues are consistent with manageable expense loads.

SLIDE 11

CAP STRUCTURE

As at January 7, 2019 Includes shares issued to date as per the Lampyon agreement, the Healthtab Agreement, and the Corozon Agreement (please note: 681,818 of the Corozon shares are subject to a year hold, expiring on May 18, 2019). ** Does not include remaining shares to be issued pursuant to the Lampyon agreement, as these shares are based on calculating the volume weighed average closing share price on the last 5 trading days preceding the date of issue

Common Shares Issued & Outstanding (per Computershare Report - January 7, 2019)   45,620,219 Reserved for Stock Options 2,566,072 Reserved for Warrants @ $0.20 - Expiry Jun 26, 2022 1,791,159 Reserved for Finders Warrants @ $0.20 - Expiry Jun 26, 2022 - All warrants have been exercised.

Reserved for Warrants @ $0.20 - Expiry Aug 3, 2022

742,667 Reserved for Warrants @ $0.20 - Expiry Nov 27, 2022 2,850,000 Reserved for Finders Warrants @ $0.20 - Expiry Nov 27, 2022 22,000 Reserved for Emerald Warrants @ $0.33 (Supply & Distribution Agreement)

Expiry April 15, 2020

3,030,303 Reserved for Warrants @ $0.33 - Expiry Jul 31, 2020 5,327,335 Reserved for Finders Warrants @ $0.33 - Expiry Jul 31, 2020 88,800 TOTAL 62,038,555

SLIDE 12

OUR PARTNERS

SLIDE 13

JOIN US IN REALIZING THIS OPPORTUNITY

Avricore Health is seeking to secure 40 Piccolo Xpress analyzers and expand the RASTR network in the immediate future. The company has no competition in this field, yet. However, as we have demonstrated here, the POCT market is rapidly growing as established health data methods get “smart.” To learn more about how you can invest in the growth of this technology, or partner with us to test your consumers, please contact us at: investor@avricorehealth.com